Rainier Therapeutics Announces Upcoming Oral and Poster Presentation on Vofatamab at AACR Bladder Cancer Conference

– Data from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer –

SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately-held clinical stage drug
development company, today announced that an abstract related to its
FIERCE-22 trial of the company’s lead therapeutic, vofatamab, has been
accepted for an oral and poster presentation at the upcoming 2019
American Association for Cancer Research (AACR) Bladder Cancer;
Transforming the Field Special Conference, taking place May 18-21, 2019
in Denver, Colorado.

“This presentation will highlight paired biopsy data from the FIERCE-22
trial of vofatamab in combination with pembrolizumab for the treatment
of relapsed metastatic bladder cancer showing vofatamab’s effects on
immune cell trafficking,” said Scott Myers, Chairman and CEO of Rainier
Therapeutics.

Presentation details:

Gene expression profiling in wild type and mutant FGFR3 metastatic
urothelial cancer treated with combination therapy with vofatamab and
pembrolizumab.

Poster Session B25

5 p.m. to 7:30 p.m., Monday, May 20, 2019

Oral session: Plenary Session 8: Management of Metastatic Disease

10:15 a.m. to Noon, Tuesday, May 21, 2019

Presenter: Woonyoung Choi, M.S., Ph.D., John Hopkins School of
Medicine

About Vofatamab

Vofatamab (formerly B-701) is an antibody specifically targeted against
the fibroblast growth factor receptor 3 (FGFR3), a known driver of
bladder and potentially other FGFR-driven cancers. Vofatamab is the most
advanced targeted antibody specific for FGFR3 known by Rainier
Therapeutics to be in clinical development. Vofatamab is currently being
evaluated in two clinical trials: FIERCE-21 and FIERCE-22.

FIERCE-22 is a Phase 2 trial evaluating vofatamab in combination with
pembrolizumab, an immune checkpoint inhibitor, to determine safety,
tolerability and efficacy in the treatment of patients with locally
advanced or metastatic bladder cancer, who have progressed following
platinum-based chemotherapy and who have not received prior immune
checkpoint inhibitor therapy. For additional information on FIERCE-22,
please visit www.clinicaltrials.gov
(NCT03123055).

About Rainier Therapeutics

Rainier Therapeutics, Inc. is a privately held, clinical stage
biotechnology company developing vofatamab, a targeted antibody, for the
potential treatment of metastatic bladder cancer. For more information,
please visit www.rainierrx.com.

Contacts

Julie Rathbun
Rathbun Communications
(206) 769-9291
[email protected]